End-of-day quote
Shanghai S.E.
18:00:00 2024-07-16 EDT
|
5-day change
|
1st Jan Change
|
3.18
CNY
|
-1.55%
|
|
0.00%
|
-37.52%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,543
|
1,976
|
2,855
|
2,094
|
1,813
|
1,489
|
Enterprise Value (EV)
1 |
1,401
|
1,884
|
2,708
|
2,275
|
2,138
|
1,840
|
P/E ratio
|
39.6
x
|
68.8
x
|
28.2
x
|
-92
x
|
-124
x
|
-9.98
x
|
Yield
|
1.35%
|
0.43%
|
1.18%
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.22
x
|
4.02
x
|
2.66
x
|
3.97
x
|
3.32
x
|
2.48
x
|
EV / Revenue
|
2.92
x
|
3.83
x
|
2.52
x
|
4.31
x
|
3.92
x
|
3.07
x
|
EV / EBITDA
|
39.6
x
|
53.4
x
|
17.3
x
|
177
x
|
144
x
|
-50.4
x
|
EV / FCF
|
-12.8
x
|
41
x
|
-72.5
x
|
-9.05
x
|
-16.9
x
|
-59.6
x
|
FCF Yield
|
-7.81%
|
2.44%
|
-1.38%
|
-11%
|
-5.91%
|
-1.68%
|
Price to Book
|
2.77
x
|
3.5
x
|
4.1
x
|
3.22
x
|
2.94
x
|
3.17
x
|
Nbr of stocks (in thousands)
|
285,610
|
285,610
|
292,734
|
292,474
|
292,474
|
292,474
|
Reference price
2 |
5.403
|
6.917
|
9.754
|
7.160
|
6.200
|
5.090
|
Announcement Date
|
3/28/19
|
4/28/20
|
4/14/21
|
4/28/22
|
4/27/23
|
3/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
479.8
|
491.7
|
1,072
|
527.4
|
545.4
|
600.1
|
EBITDA
1 |
35.4
|
35.29
|
156.8
|
12.87
|
14.86
|
-36.5
|
EBIT
1 |
24.51
|
22.53
|
136.5
|
-16.01
|
-26.36
|
-90.77
|
Operating Margin
|
5.11%
|
4.58%
|
12.73%
|
-3.03%
|
-4.83%
|
-15.13%
|
Earnings before Tax (EBT)
1 |
44.56
|
28.05
|
109.9
|
-30.69
|
-29.34
|
-148.5
|
Net income
1 |
39.25
|
28.05
|
98.07
|
-22.76
|
-14.65
|
-147.4
|
Net margin
|
8.18%
|
5.71%
|
9.14%
|
-4.32%
|
-2.69%
|
-24.57%
|
EPS
2 |
0.1366
|
0.1006
|
0.3462
|
-0.0778
|
-0.0500
|
-0.5100
|
Free Cash Flow
1 |
-109.4
|
45.97
|
-37.32
|
-251.3
|
-126.4
|
-30.85
|
FCF margin
|
-22.8%
|
9.35%
|
-3.48%
|
-47.65%
|
-23.19%
|
-5.14%
|
FCF Conversion (EBITDA)
|
-
|
130.27%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
163.87%
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.0728
|
0.0296
|
0.1154
|
-
|
-
|
-
|
Announcement Date
|
3/28/19
|
4/28/20
|
4/14/21
|
4/28/22
|
4/27/23
|
3/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
181
|
324
|
351
|
Net Cash position
1 |
142
|
91.7
|
148
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
14.06
x
|
21.83
x
|
-9.621
x
|
Free Cash Flow
1 |
-109
|
46
|
-37.3
|
-251
|
-126
|
-30.9
|
ROE (net income / shareholders' equity)
|
6.71%
|
4.46%
|
15.5%
|
-3.4%
|
-2.38%
|
-26.9%
|
ROA (Net income/ Total Assets)
|
1.84%
|
1.64%
|
8.78%
|
-0.87%
|
-1.22%
|
-4.15%
|
Assets
1 |
2,138
|
1,709
|
1,116
|
2,625
|
1,197
|
3,553
|
Book Value Per Share
2 |
1.950
|
1.980
|
2.380
|
2.220
|
2.110
|
1.600
|
Cash Flow per Share
2 |
0.8300
|
0.6800
|
1.110
|
0.5200
|
0.4400
|
0.3300
|
Capex
1 |
77.8
|
56.4
|
123
|
212
|
146
|
66.2
|
Capex / Sales
|
16.21%
|
11.46%
|
11.5%
|
40.15%
|
26.8%
|
11.02%
|
Announcement Date
|
3/28/19
|
4/28/20
|
4/14/21
|
4/28/22
|
4/27/23
|
3/29/24
|
|
1st Jan change
|
Capi.
|
---|
| -37.52% | 128M | | +28.34% | 2.68B | | +28.15% | 2.53B | | -44.68% | 2.34B | | +36.67% | 2.11B | | -31.46% | 2.05B | | -24.50% | 1.59B | | +14.55% | 1.46B | | +36.22% | 1.38B | | +18.21% | 1.26B |
Medical Supplies
|